Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. TSLA

Go back to Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
(NYSE: NSRX) Delayed: 2.88 -0.29 (9.15%)
Previous Close $3.17    52 Week High $ 
Open $3.21    52 Week Low $ 
Day High $3.24    P/E N/A 
Day Low $2.88    EPS $ 
Volume 42,183